-Rapid Case Ascertainment (RCA) Shared Resource Rapid Case Ascertainment (RCA) is a unique population science shared resource that provides central support for population-based research by providing rapid ascertainment of cancer cases that occur across North Carolina. Rapid case ascertainment (identification within one month after diagnosis) is critical to the successful conduct of quality, population-based, epidemiologic and outcomes studies, including studies that incorporate molecular biology, biomarkers, and patient-reported outcomes. Since it started in 1993, RCA supported multiple large population science research studies of breast, colon, prostate, head and neck cancers and melanoma. These included case-control etiologic studies and outcomes-related studies of bladder and prostate cancer. Built on decades of close collaboration with the State of North Carolina?s Central Cancer Registry (CCR) RCA facilitates efficient and centralized case identification. Because of its long-standing collaborative relationship with hospitals in North Carolina, RCA also works with LCCC members to collect baseline and follow-up medical records for enrolled patients. Finally, RCA provides consultation and administrative assistance to researchers through the coordination of grant applications, IRB approvals, reports to hospitals and tumor registrars, database development, and activities among project investigators, the State of North Carolina?s CCR, and related state committees. The RCA shared resource provides centralized coordination ascertainment, especially for hospitals in rural and underserved counties in the Center?s catchment area (all of North Carolina). Case-finding takes place for multiple studies across hospitals, providing a high degree of efficiency and cost effectiveness for the studies. In 2014, the facility was used to identify 16,366 new cases of breast, meningioma, prostate, cervical, colorectal, ovarian and medullary thyroid cancer cases across all 100 counties in North Carolina. A unique and valuable resource, RCA collaborated with other NCI Cancer Centers by supporting NC population research with other cancer centers in NC and outside the state. UNC Lineberger investigators continue to expand their efforts in population-based studies that rely on rapid case ascertainment. The RCA shared resource requests $73,090 in CCSG funds, representing 21% of its total budget. Future plans include the implementation of new NC population-based epidemiologic, clinical, and health services studies and working with the CCR to obtain additional follow-up on the occurrence of second primary tumors and the timely assessment of vital status of cases enrolled in epidemiologic and other population studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016086-40
Application #
8999671
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2016-03-24
Budget End
2016-11-30
Support Year
40
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Ma, Shaohua; Paiboonrungruan, Chorlada; Yan, Tiansheng et al. (2018) Targeted therapy of esophageal squamous cell carcinoma: the NRF2 signaling pathway as target. Ann N Y Acad Sci 1434:164-172
Aung, Kyaw L; Fischer, Sandra E; Denroche, Robert E et al. (2018) Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. Clin Cancer Res 24:1344-1354
Suh, Junghyun L; Watts, Brian; Stuckey, Jacob I et al. (2018) Quantitative Characterization of Bivalent Probes for a Dual Bromodomain Protein, Transcription Initiation Factor TFIID Subunit 1. Biochemistry 57:2140-2149
Brock, William J; Beaudoin, James J; Slizgi, Jason R et al. (2018) Bile Acids as Potential Biomarkers to Assess Liver Impairment in Polycystic Kidney Disease. Int J Toxicol 37:144-154
Thomas, Nancy E; Edmiston, Sharon N; Tsai, Yihsuan S et al. (2018) Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis. Am J Dermatopathol :
Bensen, Jeannette T; Graff, Mariaelisa; Young, Kristin L et al. (2018) A survey of microRNA single nucleotide polymorphisms identifies novel breast cancer susceptibility loci in a case-control, population-based study of African-American women. Breast Cancer Res 20:45
Hall, Marissa G; Marteau, Theresa M; Sunstein, Cass R et al. (2018) Public support for pictorial warnings on cigarette packs: an experimental study of US smokers. J Behav Med 41:398-405
Thorsson, Vésteinn; Gibbs, David L; Brown, Scott D et al. (2018) The Immune Landscape of Cancer. Immunity 48:812-830.e14
Wu, Bing; Zhang, Song; Guo, Zengli et al. (2018) RAS P21 Protein Activator 3 (RASA3) Specifically Promotes Pathogenic T Helper 17 Cell Generation by Repressing T-Helper-2-Cell-Biased Programs. Immunity 49:886-898.e5
Ding, Li; Bailey, Matthew H; Porta-Pardo, Eduard et al. (2018) Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell 173:305-320.e10

Showing the most recent 10 out of 1525 publications